Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Interest Income
Income earned on cash, deposits, and investments held by the company.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income dips below year-ago levels
Q1 FY2026 interest income of $4.08M fell 18.6% year over year, behind the +1.3% change in trailing-twelve-month interest income. Sequentially, it rose 7.8% from the prior quarter. Over 3 fiscal years it compounded at +1547.0% a year.
Context
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -18.6% toward the trailing-twelve-month pace of +1.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 17.87M USD
- Year-over-year change
- +22.6%
- 3-year CAGR
- +1547.0%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.87M | +22.6% |
| FY2024 | 2024-12-31 | 14.58M | +1009.7% |
| FY2023 | 2023-12-31 | 1.31M | +32750.0% |
| FY2022 | 2022-12-31 | 4K | — |
Interest Income vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's LTM Mar 2026 interest income of $16.94M is the 2nd highest of the 6 companies compared; the peer median is $5.93M.
- Its year-over-year change of +1.3% is the 3rd highest of 6, against a peer median of -26.6%.
- Over three fiscal years its annual growth of +1547.0% compares with a peer median of +49.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.73M | -35.4% | +49.8% | — | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $16.94M | +1.3% | +1547.0% | — |
| LTM Mar 2026 | $7M | +5.2% | +39.1% | — | |
| LTM Mar 2026 | $5.93M | -29.4% | +26.0% | 3.8% | |
| LTM Mar 2026 | $4.13M | +409.6% | +59.1% | 34.8% | |
| LTM Mar 2026 | $2.94M | -26.6% | +83.4% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $5.93M | -26.6% | +49.8% | 19.3% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 31.31M | 30.62M | 63.62M | 125.1M |
| Selling, General & Admin | 6.34M | 9.27M | 18.77M | 30.51M |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 155.6M |
| Depreciation & Amortization | 10K | 19K | 56K | 105K |
| EBITDA | (37.72M) | (51.96M) | (67.75M) | (137.63M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (37.66M) | (39.89M) | (82.39M) | (155.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 4K | 1.31M | 14.58M | 17.87M |
| Interest Expense | 112K | 0 | 0 | 0 |
| Other Income / Expenses | (188K) | (12.09M) | 14.58M | 17.87M |
| Income Before Tax | (37.84M) | (51.98M) | (67.81M) | (137.73M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 5K | 187K | 217K |
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.73) | (1.00) | (1.25) | (2.52) |
| EPS (Diluted) | (0.73) | (1.00) | (1.25) | (2.52) |
| Weighted Avg Shares | 51.76M | 51.76M | 54.42M | 54.68M |
| Weighted Avg Shares (Diluted) | 51.76M | 51.76M | 54.42M | 54.68M |
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.